Morgan Stanley Downgrades Inspire Pharmaceuticals (ISPH) to Underweight
More News related to ISPH
- Inspire Announces Presentations at European Cystic Fibrosis Society Annual Meeting
- Inspire Announces Webcast of Presentation at Needham Life Sciences Conference
- Inspire Announces Presentations at American Thoracic Society Annual Meeting
- Inspire Announces Webcast of Presentation at Deutsche Bank Health Care Conference
- Wedbush Morgan Downgrades Inspire Pharmaceuticals (ISPH) To Buy
Morgan Stanley downgrades Inspire Pharmaceuticals (Nasdaq: ISPH) from Equalweight to Underweight.
Inspire Pharmaceuticals, Inc. (Inspire) is a biopharmaceutical company focusing on discovering, developing and commercializing prescription pharmaceutical products in disease areas with commercial potential or unmet medical needs.
Related Categories
DowngradesStocks Mentioned
-0.16Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
